Julie Linn
Gilbert, AZNPI 1679120547
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 361 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations.
Across 361 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$606
- AstraZeneca$603
- Amgen$513
- Xeris Pharmaceuticals, Inc.$488
- Sanofi-aventis U.S. LLC$413
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,113100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 64 | $1,042 |
| Novo Nordisk | 38 | $606 |
| AstraZeneca(2 entities) | 26 | $603 |
| Amgen(2 entities) | 31 | $513 |
| Xeris Pharmaceuticals, Inc. | 26 | $488 |
| Sanofi-aventis U.S. LLC | 17 | $413 |
| Corcept Therapeutics | 13 | $402 |
| Boehringer Ingelheim | 20 | $394 |
| Bayer | 13 | $327 |
| Amneal Pharmaceuticals LLC | 11 | $245 |
| Antares Pharma, Inc. | 14 | $234 |
| Radius Health, Inc. | 13 | $225 |
| Medtronic | 13 | $221 |
| Mannkind Corporation | 11 | $211 |
| Recordati_rare_diseases_inc. | 8 | $191 |
| AbbVie | 9 | $169 |
| Kyowa Kirin, Inc. | 5 | $133 |
| Ferring Pharmaceuticals Inc. | 1 | $119 |
| Insulet Corporation | 4 | $97 |
| IBSA Pharma Inc. | 4 | $94 |
| Averitas Pharma Inc. | 3 | $68 |
| Madrigal Pharmaceuticals | 2 | $48 |
| Astellas Pharma US Inc | 2 | $43 |
| Abbott | 2 | $41 |
| Acella Pharmaceuticals, LLC | 2 | $36 |
| Amryt Pharma Holdings Ltd | 2 | $25 |
| Novartis | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 33 | $1,138,647 |
| OzempicSemaglutide | 334 | $580,586 |
| TrulicityDulaglutide | 163 | $296,572 |
| JardianceEmpagliflozin | 200 | $229,388 |
| MounjaroTirzepatide | 94 | $141,944 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $115,464 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 65 | $105,509 |
| FarxigaDapagliflozin Propanediol | 60 | $76,809 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 78 | $75,516 |
| Tresiba Flextouch U-100Insulin Degludec | 70 | $68,778 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $59,440 |
| RybelsusSemaglutide | 37 | $55,727 |
| JanuviaSitagliptin Phosphate | 39 | $37,518 |
| TymlosAbaloparatide | 12 | $37,164 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 198 | $30,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $402 | $1,138,64733 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $606 | $640,742385 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,042 | $453,826306 claims |
| Boehringer IngelheimJardiance, Tradjenta | $394 | $255,437223 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $413 | $79,958101 claims |
| AstraZenecaFarxiga | $603 | $76,80960 claims |
| MerckJanuvia | $14 | $37,51839 claims |
| Radius Health, Inc.Tymlos | $225 | $37,16412 claims |
| AmgenProlia | $513 | $22,93713 claims |
| IBSA Pharma Inc.Tirosint, Tirosint-Sol | $94 | $11,48333 claims |
| AbbVieSynthroid | $169 | $7,747105 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $245 | $4,144455 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.